An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2018
Price : $35 *
At a glance
- Drugs Alpelisib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 15 Jul 2018 Planned number of patients changed from 51 to 43.
- 15 Jul 2018 Planned End Date changed from 1 Mar 2018 to 1 May 2019.
- 15 Jul 2018 Planned primary completion date changed from 1 Sep 2017 to 1 May 2019.